# NEO-811

Source: https://onco.cc/drugs/neo-811/  
OnCo record `neo-811` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NEO-811 is an experimental molecular glue degrader from Neomorph, in phase 1 trials for clear cell renal cell carcinoma.

## Summary

NEO-811 (NEO811) is a molecular glue degrader (cereblon-dependent) from Neomorph. An investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein and fully block a central signalling pathway in clear cell renal cell carcinoma; the pipeline page names the target as ARNT/HIF-1beta. Its furthest stage is phase 1, for clear cell renal cell carcinoma. ClinicalTrials.gov registers it in one study linked below. First patient dosed in phase 1/2 NEO-811-101 (NCT07300241), announced 3 Feb 2026; registry lists PHASE1, recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: NEO811
- Tags: pipeline; ctgov-ingest
- Code: NEO-811
- Modality: Molecular glue degrader (cereblon-dependent)
- Mechanism: An investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein and fully block a central signalling pathway in clear cell renal cell carcinoma; the pipeline page names the target as ARNT/HIF-1beta.

## Sources

- Neomorph: neomorph.com: https://neomorph.com/pipeline/
- Neomorph: neomorph.com: https://neomorph.com/press-release/neomorph-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-neo-811-for-the-treatment-of-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma/
- Neomorph: neomorph.com: https://neomorph.com/press-release/neomorph-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-neo-811-for-the-treatment-of-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma/
- ClinicalTrials.gov: trials of NEO-811: https://clinicaltrials.gov/search?intr=NEO-811

## Connected records

- cancers: [Clear cell renal cell carcinoma](https://onco.cc/cancers/clear-cell-rcc/)
- targets: [ARNT](https://onco.cc/targets/arnt/)
- companies: [Neomorph](https://onco.cc/companies/neomorph/)
- trials: [Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma](https://onco.cc/trials/nct07300241/)

---
JSON: https://onco.cc/api/v1/entities/neo-811.json